LivaNova (NASDAQ:LIVN) Stock Rating Upgraded by Freedom Capital

LivaNova (NASDAQ:LIVN) was upgraded by equities researchers at Freedom Capital to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

LIVN has been the subject of a number of other research reports. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Robert W. Baird decreased their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Mizuho raised their price target on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. KeyCorp lifted their price target on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd. Finally, Barclays boosted their price objective on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and an average price target of $80.75.

LivaNova Stock Performance

LivaNova stock opened at $83.62 on Tuesday. LivaNova has a fifty-two week low of $41.01 and a fifty-two week high of $83.98. The company has a market capitalization of $4.59 billion, a price-to-earnings ratio of 42.88 and a beta of 0.86. The stock has a fifty day moving average of $73.58 and a two-hundred day moving average of $67.51. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. During the same period in the prior year, the business earned $0.88 earnings per share. The business’s revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, analysts anticipate that LivaNova will post 3.73 EPS for the current fiscal year.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the sale, the director directly owned 7,228 shares in the company, valued at $547,521. This represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.35% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LivaNova

Several hedge funds and other institutional investors have recently modified their holdings of LIVN. Hantz Financial Services Inc. grew its holdings in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after purchasing an additional 267 shares during the period. State of Wyoming acquired a new stake in LivaNova during the 2nd quarter worth approximately $31,000. Quarry LP purchased a new position in LivaNova in the third quarter valued at approximately $36,000. EverSource Wealth Advisors LLC raised its holdings in LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares during the period. Finally, Covestor Ltd raised its holdings in LivaNova by 108.6% in the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after buying an additional 392 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.